For instance, in a phase 2 study involving patients with NASH, 12 weeks of Aldafermin (FGF-19 analogues) reduced absolute liver fat, as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF), by 5% in 80% of the patients. Here, FGF19 is linked to metabolic dysfunction-associated steatohepatitis.